Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review

  • Zeeshanuddin AhmadEmail author
  • Amar Jain
  • Nikhil Mehta
  • Elroy Saldanha
  • Dhruv Patel
  • Sanjay M. Desai
Original Article



To compare the overall survival of women with advanced-stage EOC treated by PCS versus NACT followed by IDS.

Design, Setting, and Participants

Retrospective study of women with stage IIB–IVA ovarian carcinoma FIGO staging diagnosed between 2016 and 2018 treated at Department of Surgical Oncology, Sri Aurobindo Medical College and Post Graduate Institute, Indore.


Initial treatment approach of PCS versus NACT + IDS, examined using an intent-to-treat analysis.


The median follow-up was 18 months (10–36 months) in both groups. The median overall survival was 38 months in PCS group and 31 months in NACT group. Postoperative complications were seen more often in PCS group (11.3%) against 3.33% in NACT group. Patients with residual disease (microscopic and macroscopic residual disease) had poorer prognosis.


Primary cytoreductive surgery is associated with improved survival compared with NACT in otherwise healthy women with bulky epithelial ovarian. The biggest risk associated with the use of NACT is that patients with significant side effects and refractory disease will lose the opportunity for initial surgery. The lower survival in women receiving NACT can be owed to limited performance status in women undergoing NACT.


Epithelial ovarian cancer (EOC) Primary cytoreductive surgery (PCS) Interval debulking surgery (IDS) Neoadjuvant chemotherapy (NACT) 


Compliance with Ethical Standards

Conflict of interest

The authors have no potential conflict of interest to disclose.


  1. 1.
    Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer (IARC). 2013.
  2. 2.
    Ziebarth AJ, Landen CN, Alvarez RD. Molecular/genetic therapies in ovarian cancer. Clin Obstet Gynecol. 2012;55(1):156–72. Scholar
  3. 3.
    Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–29. Scholar
  4. 4.
    Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe D’Investigateurs Nationaux Pour Les Etudes Des Cancers De L’Ovaire (GINECO). Cancer. 2009;115:1234–44. Scholar
  5. 5.
    Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59. Scholar
  6. 6.
    Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53. Scholar
  7. 7.
    Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2005;386(9990):249–57. Scholar
  8. 8.
    Morgan RJ Jr, Alvarez RD, Armstrong DK, et al. National comprehensive cancer network. Ovarian cancer: clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2006;4(9):912–39. Scholar
  9. 9.
    Worley MJ, Guseh SH, Rauh-Hain JA, Esselen KM, Muto MG, Feltmate CM, et al. What is the optimal treatment for obese patients with advanced ovarian carcinoma? Am J Obstet Gynecol. 2014;211(3):231.e1–9. Scholar
  10. 10.
    Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Gynecol Oncol. 2006;103(3):1083–90. Scholar
  11. 11.
    Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 1992;47(2):159–66. Scholar
  12. 12.
    Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107(1):77–85. Scholar
  13. 13.
    Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31. Scholar
  14. 14.
    Van Meurs HS, Tajik P, Hof MHP, Vergote I, Kenter GG, Mol BWJ, et al. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer. 2013;49(15):3191–201. Scholar
  15. 15.
    Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124(1):10–4. Scholar
  16. 16.
    Fagotti A, De Iaco P, Fanfani F, Vizzielli G, Perelli F, Pozzati F, et al. Systematic pelvic and aortic lymphadenectomy in advanced ovarian cancer patients at the time of interval debulking surgery: a double-institution case-control study. Ann Surg Oncol. 2012;19(11):3522–7. Scholar
  17. 17.
    Fagö-Olsen CL, Ottesen B, Kehlet H, Antonsen SL, Christensen IJ, Markauskas A, et al. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study. Gynecol Oncol. 2004;32(2):292–8. Scholar
  18. 18.
    Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi D-A, Santin AD, et al. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). J Surg Oncol. 2012;107(2):195–200. Scholar
  19. 19.
    Sehouli J, Savvatis K, Braicu EI, et al. Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. Int J Gynecol Cancer. 2010;20:1331–40. Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2019

Authors and Affiliations

  • Zeeshanuddin Ahmad
    • 1
    Email author
  • Amar Jain
    • 1
  • Nikhil Mehta
    • 1
  • Elroy Saldanha
    • 1
  • Dhruv Patel
    • 1
  • Sanjay M. Desai
    • 1
  1. 1.Department of Surgical OncologySri Aurobindo Medical College and Post Graduate InstituteIndoreIndia

Personalised recommendations